- Home
- INVE vs AVTX Comparison
INVE vs AVTX Comparison
Compare INVE & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- AVTX
- Stock Information
- Founded
- INVE 1990
- AVTX 2011
- Country
- INVE United States
- AVTX United States
- Employees
- INVE N/A
- AVTX N/A
- Industry
- INVE Computer peripheral equipment
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- AVTX Health Care
- Exchange
- INVE Nasdaq
- AVTX Nasdaq
- Market Cap
- INVE 82.2M
- AVTX 88.4M
- IPO Year
- INVE 1997
- AVTX 2015
- Fundamental
- Price
- INVE $3.44
- AVTX $8.44
- Analyst Decision
- INVE Strong Buy
- AVTX Strong Buy
- Analyst Count
- INVE 2
- AVTX 4
- Target Price
- INVE $7.25
- AVTX $33.00
- AVG Volume (30 Days)
- INVE 31.8K
- AVTX 37.8K
- Earning Date
- INVE 03-05-2025
- AVTX 03-28-2025
- Dividend Yield
- INVE N/A
- AVTX N/A
- EPS Growth
- INVE N/A
- AVTX N/A
- EPS
- INVE 3.10
- AVTX N/A
- Revenue
- INVE $104,217,000.00
- AVTX $820,000.00
- Revenue This Year
- INVE N/A
- AVTX N/A
- Revenue Next Year
- INVE N/A
- AVTX N/A
- P/E Ratio
- INVE $1.13
- AVTX N/A
- Revenue Growth
- INVE 70.57
- AVTX N/A
- 52 Week Low
- INVE $2.95
- AVTX $4.24
- 52 Week High
- INVE $9.24
- AVTX $34.46
- Technical
- Relative Strength Index (RSI)
- INVE 40.36
- AVTX 57.77
- Support Level
- INVE $3.41
- AVTX $6.81
- Resistance Level
- INVE $3.67
- AVTX $8.00
- Average True Range (ATR)
- INVE 0.19
- AVTX 0.56
- MACD
- INVE 0.01
- AVTX 0.03
- Stochastic Oscillator
- INVE 12.20
- AVTX 81.99
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has two reportable segments namely the Premises segment which includes solutions to address the premises security market for government and enterprise, including access control, video surveillance, analytics, customer experience, and other applications. Its Identity segment includes products and solutions enabling secure access to information serving the logical access and cyber security market and protecting assets and objects in the IoT with RFID. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific. The company derives the majority of revenue from the Identity segment.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).